Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG60ET)

• Drug Name: GW-3965 Drug Info
• Synonyms: GW3965; 405911-09-3; GW 3965; UNII-6JI5YOG7RC; GW-3965; 6JI5YOG7RC; CHEMBL59030; CHEBI:79995; (3-{3-[[2-CHLORO-3-(TRIFLUOROMETHYL)BENZYL](2,2-DIPHENYLETHYL)AMINO]PROPOXY}PHENYL)ACETIC ACID; 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-[2,2-di(phenyl)ethyl]amino]propoxy]phenyl]acetic acid; [3-(3-{[2-Chloro-3-(Trifluoromethyl)benzyl](2,2-Diphenylethyl)amino}propoxy)phenyl]acetic Acid; GW-3965A; 3-(3-[[2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)-amino]-propoxy}-phenyl acetic acid; GW 3965A

Indication

Disease Entry	ICD 11	Status	REF
Major depressive disorder	6A70.3	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 447905
  ChEBI ID: CHEMBL59030
  CAS Number: CAS 405911-09-3
  TTD Drug ID: DMG60ET

Molecule-Related Drug Atlas

Drug(s) Targeting Oxysterols receptor LXR-beta (NR1H2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VTB-38543	DMNY3J0	Atopic dermatitis	EA80	Phase 2	[6]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[7]
desmosterol	DMV8SUM	Discovery agent	N.A.	Investigative	[8]
L-783483	DM6OTGE	Discovery agent	N.A.	Investigative	[9]
WAY-214950	DM8ODI7	Discovery agent	N.A.	Investigative	[2]
27-hydroxycholesterol	DM2L6OZ	Discovery agent	N.A.	Investigative	[10]
22R-hydroxycholesterol	DME8273	Discovery agent	N.A.	Investigative	[11]
GSK-9772	DM4WS3R	Discovery agent	N.A.	Investigative	[12]
Riccardin C	DM6MYGX	Discovery agent	N.A.	Investigative	[13]
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione	DMH76SO	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting Oxysterols receptor LXR-alpha (NR1H3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9073931, E2	DMK9FJG	N. A.	N. A.	Patented	[15]
BDBM50177019	DMEL28G	N. A.	N. A.	Patented	[16]
US9006244, E2b	DMP0TBO	N. A.	N. A.	Patented	[17]
US9073931, E1	DM2Z43I	N. A.	N. A.	Patented	[15]
US9006244, E1	DMBF1C0	N. A.	N. A.	Patented	[17]
BDBM50177012	DM52IQF	N. A.	N. A.	Patented	[16]
US9006244, E2a	DMPDF9B	N. A.	N. A.	Patented	[17]
67S	DMJL1MB	N. A.	N. A.	Patented	[16]
US9073931, E3	DMCYM8P	N. A.	N. A.	Patented	[15]
desmosterol	DMV8SUM	Discovery agent	N.A.	Investigative	[8]

Drug(s) Affected By Steroidogenic acute regulatory protein, mitochondrial (STAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[18]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[25]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[26]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[27]

Drug(s) Affected By Tumor necrosis factor ligand superfamily member 15 (TNFSF15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[29]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[32]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[33]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[34]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[35]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[36]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[37]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[38]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[39]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[40]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[41]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[42]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[43]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[44]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[45]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[43]

Drug(s) Affected By Transcription factor E2F3 (E2F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[46]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[48]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[51]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[32]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[48]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[34]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[52]

Drug(s) Affected By Stearoyl-CoA desaturase (SCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[53]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[54]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[54]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[55]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[57]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[54]
Fructose	DM43AN2	Vomiting	MD90	Approved	[58]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[59]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[54]

Drug(s) Affected By Insulin-induced gene 1 protein (INSIG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[60]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[64]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[65]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[63]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[66]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[67]

Drug(s) Affected By Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[70]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[73]

Drug(s) Affected By Dual specificity protein phosphatase CDC14B (CDC14B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[74]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[65]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[75]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[56]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[77]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[78]

Drug(s) Affected By Cell division control protein 45 homolog (CDC45)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[79]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[82]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[83]

Drug(s) Affected By Phospholipid-transporting ATPase ABCA1 (ABCA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[84]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[85]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[61]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[86]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[87]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[90]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[91]

Drug(s) Affected By Fatty acid-binding protein, adipocyte (FABP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[92]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[93]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[57]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[94]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[95]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[87]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[96]

Drug(s) Affected By DNA replication licensing factor MCM3 (MCM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[97]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[98]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[99]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]

Drug(s) Affected By Retinoblastoma-like protein 1 (RBL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[100]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[46]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[102]

Drug(s) Affected By M-phase inducer phosphatase 1 (CDC25A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[103]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[104]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[105]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[106]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[107]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[108]

Drug(s) Affected By M-phase inducer phosphatase 3 (CDC25C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[103]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[48]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[109]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[110]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]

Drug(s) Affected By DNA replication licensing factor MCM4 (MCM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[103]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[79]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[29]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[111]

Drug(s) Affected By DNA replication licensing factor MCM5 (MCM5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[97]
Selenium	DM25CGV	N. A.	N. A.	Approved	[74]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[112]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[98]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[113]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]

Drug(s) Affected By Alpha-synuclein (SNCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[29]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[51]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[114]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[115]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[116]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[52]
Bortezomib	DMNO38U	Leukemia		Approved	[117]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[118]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[119]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 2A (CDKN2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[120]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[121]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[106]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[123]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[125]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[126]

Drug(s) Affected By Cyclin-dependent kinase 4 inhibitor B (CDKN2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[127]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[103]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[121]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[128]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[129]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[56]

Drug(s) Affected By DNA replication licensing factor MCM2 (MCM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[130]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[112]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[131]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[115]

Drug(s) Affected By Transcription factor E2F1 (E2F1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[132]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[130]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[133]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[134]
Selenium	DM25CGV	N. A.	N. A.	Approved	[74]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[104]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[135]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[79]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]

Drug(s) Affected By POU domain, class 5, transcription factor 1 (POU5F1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[136]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[137]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[138]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[139]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[141]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[142]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[143]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[21]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[144]

Drug(s) Affected By Origin recognition complex subunit 1 (ORC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[130]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[29]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[98]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[111]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[83]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[145]

Drug(s) Affected By Transcription factor Dp-1 (TFDP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[59]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[98]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[94]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[34]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[52]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[146]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[147]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[148]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[149]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[97]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[53]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[148]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[150]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[151]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[148]

Drug(s) Affected By E3 ubiquitin-protein ligase MYLIP (MYLIP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[29]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[140]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[152]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[153]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[32]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[52]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[154]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[155]

Drug(s) Affected By Carbohydrate-responsive element-binding protein (MLXIPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[94]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[156]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[154]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[119]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[157]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[159]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[160]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]

Drug(s) Affected By Dual specificity protein phosphatase CDC14A (CDC14A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[161]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[80]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[32]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[35]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[162]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[163]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[160]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[140]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[164]

Drug(s) Affected By Origin recognition complex subunit 6 (ORC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[56]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[71]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[31]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[56]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[94]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[165]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxysterols receptor LXR-alpha (NR1H3)	TTECBXN	NR1H3_HUMAN	Inhibitor	[2]
Oxysterols receptor LXR-beta (NR1H2)	TTXA6PH	NR1H2_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-synuclein (SNCA)	OTPWC1MR	SYUA_HUMAN	Gene/Protein Processing	[3]
Carbohydrate-responsive element-binding protein (MLXIPL)	OTR9MLLW	MLXPL_HUMAN	Gene/Protein Processing	[4]
Cell division control protein 45 homolog (CDC45)	OT6NNLOD	CDC45_HUMAN	Gene/Protein Processing	[5]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B)	OTAG24N1	CDN2B_HUMAN	Gene/Protein Processing	[5]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Gene/Protein Processing	[5]
DNA replication licensing factor MCM2 (MCM2)	OTGGORIQ	MCM2_HUMAN	Gene/Protein Processing	[5]
DNA replication licensing factor MCM3 (MCM3)	OTOOHQPM	MCM3_HUMAN	Gene/Protein Processing	[5]
DNA replication licensing factor MCM4 (MCM4)	OT19PNNG	MCM4_HUMAN	Gene/Protein Processing	[5]
DNA replication licensing factor MCM5 (MCM5)	OTAHLB62	MCM5_HUMAN	Gene/Protein Processing	[5]
Dual specificity protein phosphatase CDC14A (CDC14A)	OTL10OY6	CC14A_HUMAN	Gene/Protein Processing	[5]

References

• [1] Liver X receptor in the hippocampus: A potential novel target for the treatment of major depressive disorder Neuropharmacology. 2018 Jun;135:514-528.
• [2] Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
• [3] Regulation of alpha-synuclein expression by liver X receptor ligands in vitro. Neuroreport. 2008 Nov 19;19(17):1685-9. doi: 10.1097/WNR.0b013e32831578b2.
• [4] Combinations of LXR and RXR agonists induce triglyceride accumulation in human HepaRG cells in a synergistic manner. Arch Toxicol. 2020 Apr;94(4):1303-1320. doi: 10.1007/s00204-020-02685-7. Epub 2020 Mar 2.
• [5] System analysis of cross-talk between nuclear receptors reveals an opposite regulation of the cell cycle by LXR and FXR in human HepaRG liver cells. PLoS One. 2019 Aug 22;14(8):e0220894. doi: 10.1371/journal.pone.0220894. eCollection 2019.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [8] Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
• [9] A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
• [10] 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
• [11] An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
• [12] Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
• [13] Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
• [14] Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
• [15] Liver X receptor modulators. US9073931.
• [16] Piperazine derivatives as liver X receptor modulators. US10144715.
• [17] Liver X receptor modulators. US9006244.
• [18] Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Aug;90(8):4858-65. doi: 10.1210/jc.2005-0330. Epub 2005 May 24.
• [19] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [20] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [21] Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
• [22] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [23] Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro. J Appl Toxicol. 2006 Nov-Dec;26(6):484-92.
• [24] Differential effects of antiepileptic drugs on steroidogenesis in a human in vitro cell model. Acta Neurol Scand Suppl. 2009;(189):14-21.
• [25] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [26] Glucocorticoid-activation system mediated glucocorticoid-insulin-like growth factor 1 (GC-IGF1) axis programming alteration of adrenal dysfunction induced by prenatal caffeine exposure. Toxicol Lett. 2019 Mar 1;302:7-17.
• [27] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [28] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [29] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [30] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [31] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [32] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [33] Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. doi: 10.1111/j.1365-2567.2007.02574.x. Epub 2007 Mar 7.
• [34] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [35] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [36] Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci. 2014 Jun;139(2):328-37. doi: 10.1093/toxsci/kfu053. Epub 2014 Mar 27.
• [37] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [38] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [39] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [40] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [41] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [42] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [43] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [44] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [45] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [46] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [47] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [48] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [49] Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem. 2010 Dec 15;111(6):1546-55. doi: 10.1002/jcb.22886.
• [50] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [51] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [52] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [53] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [54] Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
• [55] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [56] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [57] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [58] Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
• [59] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [60] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [61] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [62] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [63] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [64] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [65] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [66] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [67] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [68] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [69] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [70] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [71] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [72] Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis. Toxicol Appl Pharmacol. 2009 Apr 15;236(2):231-8. doi: 10.1016/j.taap.2009.02.003. Epub 2009 Feb 12.
• [73] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [74] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [75] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [76] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [77] Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
• [78] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [79] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [80] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [81] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [82] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [83] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [84] Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
• [85] Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
• [86] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [87] Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
• [88] Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.
• [89] Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
• [90] Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
• [91] Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
• [92] Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
• [93] Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
• [94] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [95] Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One. 2013 Dec 3;8(12):e82086. doi: 10.1371/journal.pone.0082086. eCollection 2013.
• [96] Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
• [97] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [98] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [99] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [100] Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. J Biol Chem. 2003 May 23;278(21):19509-17. doi: 10.1074/jbc.M300511200. Epub 2003 Mar 5.
• [101] Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4). Ann Hematol. 2018 Jan;97(1):83-93. doi: 10.1007/s00277-017-3163-y. Epub 2017 Nov 20.
• [102] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [103] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [104] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [105] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [106] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [107] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [108] Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18827-32. doi: 10.1073/pnas.1210037109. Epub 2012 Oct 29.
• [109] Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000 Jun 1;60(11):3065-71.
• [110] Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
• [111] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [112] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [113] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [114] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [115] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [116] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [117] Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer. 2007 Oct 22;97(8):1099-105. doi: 10.1038/sj.bjc.6604003. Epub 2007 Sep 25.
• [118] The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009 Feb;41(2):178-186.
• [119] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [120] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [121] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [122] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [123] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [124] [Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide]. Ai Zheng. 2004 Jun;23(6):626-30.
• [125] p16 loss facilitate hydroquinone-induced malignant transformation of TK6 cells through promoting cell proliferation and accelerating the cell cycle progression. Environ Toxicol. 2021 Aug;36(8):1591-1599. doi: 10.1002/tox.23155. Epub 2021 May 1.
• [126] Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. 2008;47(6):1062-70.
• [127] ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
• [128] Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. Stem Cells. 2007 Mar;25(3):771-8. doi: 10.1634/stemcells.2006-0271. Epub 2006 Nov 30.
• [129] Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity. Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):28-31.
• [130] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [131] High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009 Oct 1;15(19):6070-8.
• [132] Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med. 2004 Jan;10(1):40-7. doi: 10.1038/nm969. Epub 2003 Dec 14.
• [133] Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
• [134] Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
• [135] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [136] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [137] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [138] Quercetin in elimination of tumor initiating stem-like and mesenchymal transformation property in head and neck cancer. Head Neck. 2013 Mar;35(3):413-9. doi: 10.1002/hed.22982. Epub 2012 Mar 16.
• [139] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
• [140] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [141] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [142] Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med. 2021 Feb;11(2):e335. doi: 10.1002/ctm2.335.
• [143] Altered expression of genes identified in rats with prostatic chronic inflammation in a prostate spheroid model treated by estradiol/testosterone. J Toxicol Sci. 2021;46(11):515-523. doi: 10.2131/jts.46.515.
• [144] Effects of Exposure to Acetaminophen and Ibuprofen on Fetal Germ Cell Development in Both Sexes in Rodent and Human Using Multiple Experimental Systems. Environ Health Perspect. 2018 Apr 16;126(4):047006. doi: 10.1289/EHP2307.
• [145] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [146] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [147] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [148] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [149] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [150] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [151] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [152] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [153] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [154] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [155] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [156] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [157] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [158] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [159] Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
• [160] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [161] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [162] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [163] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [164] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [165] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.